Healthcare / BiotechnologyNasdaqCM
$0.86
+0.05 (+6.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-13.1M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$208M
P/E
0.0x
↓EV/EBITDA
N/A
•ROE
63.9%
↑Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $1.24B · FCF $-10.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $1.24B | $1.24B | $-15.0M | $-29.1M | $-31.1M |
| EBITDA | $-14.7M | $-14.7M | $-14.4M | $-24.3M | $-25.0M |
| EPS | — | — | -0.73 | -1.56 | -1.69 |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.02 | 0.03 | 0.09 |
| Current Ratio | 193.24 | 193.24 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.5M | $-10.5M | $-13.1M | $-23.8M | $-32.1M |
| Returns | |||||
| ROE | 63.9% | 63.9% | -63.6% | -96.6% | -54.6% |
| Valuation | |||||
| P/E | 0.03 | 0.03 | — | — | — |
| P/B | 0.11 | 0.11 | 1.09 | 2.24 | 1.38 |
| Growth & Yield | |||||
| EPS Growth | — | — | 53.2% | 7.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.73 → n/d
Residual
-7.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.